id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S6621 R18187 |
Burja (Carbamazepine) (Controls unexposed, disease free), 2006 | Intracranial hemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, disease free excluded | Adjustment: No |
10.99 [2.67;45.25] C excluded (control group) |
4/19 5/211 | 9 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5591 R18141 |
Burja (Carbamazepine) (Controls unexposed, sick), 2006 | Intracranial hemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 4.00 [0.66;24.37] C | 4/19 2/32 | 6 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6685 R18599 |
D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 | Periventricular haemorrhage (germinal layer) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
24.60 [0.40;1512.72] C excluded (control group) |
0/3 0/62 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6689 R18716 |
D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 | Periventricular haemorrhage (germinal layer) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 3.00 [0.05;194.76] C | 0/3 0/8 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 3.82 [0.73;20.07] | 6 | 22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6685, 6621